Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Non-Current Liabilities (2016 - 2025)

Sutro Biopharma's Total Non-Current Liabilities history spans 10 years, with the latest figure at $295.2 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 12.89% year-over-year to $295.2 million; the TTM value through Sep 2025 reached $295.2 million, down 12.89%, while the annual FY2024 figure was $340.9 million, 6.74% up from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $295.2 million at Sutro Biopharma, up from $292.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $345.5 million in Q1 2025 and bottomed at $50.6 million in Q1 2021.
  • The 5-year median for Total Non-Current Liabilities is $241.3 million (2022), against an average of $216.8 million.
  • The largest annual shift saw Total Non-Current Liabilities fell 29.44% in 2021 before it skyrocketed 242.94% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $88.7 million in 2021, then surged by 113.96% to $189.8 million in 2022, then soared by 68.3% to $319.4 million in 2023, then rose by 6.74% to $340.9 million in 2024, then decreased by 13.4% to $295.2 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Total Non-Current Liabilities are $295.2 million (Q3 2025), $292.8 million (Q2 2025), and $345.5 million (Q1 2025).